Regsiter now for a personalized educational experience.
Already a member? Log In
By linking your Doximity account with UPMC Physician Resources, you acknowledge that:
Forgot your password? Enter the email address you used to create your account to initiate a password reset.
Professor of Medicine and Biomedical Informatics Associate Chief for Translational Research Division of Gastroenterology, Hepatology and Nutrition University of Pittsburgh School of Medicine
Division of Gastroenterology, Hepatology & Nut (CLD) Center for Liver Diseases
3471 5th Ave 916 Lillian Kaufmann Building
Pittsburgh, PA 15213 Phone: 412-647-4932
BS, University of Notre Dame, 1968
MD, Northwestern University Medical School, 1971
Medical Internship, University of Michigan Medical Center, Ann Arbor, MI, 1972
Medical Residency, Hospital of the University of Pennsylvania, Philadelphia, PA, 1974
Gastroenterology Fellowship, Albert Einstein College of Medicine, Bronx, NY, 1977
Dr. Dunn is a Professor of Medicine. In collaboration with colleagues of the Thomas E Starzl Transplantation Institute and the School of Health and Rehabilitation Sciences, he leads a UPMC hospital-funded initiative to improve the fitness and activity of liver transplant candidates with the objective of producing a 20% decrease in waitlist hospital days and waitlist mortality. Wearable personal activity monitoring and quantitation of muscle mass with imaging segmentation analysis are being explored as enabling technologies.
Dr. Dunn formed and now leads the FLEXIT (Fitness, Life Enhancement and Exercise in Transplantation) Consortium of investigators at the University of California San Francisco, Mayo Clinic Arizona, Cleveland Clinic, Duke University, University of Alberta, and University of Pittsburgh, engaged in multi-center collaborations to define, prevent and reverse physical decline in cirrhosis.
Dr. Dunn helped Dr. David Binion design and continue to assist in operating a Department of Defense supported searchable prospective electronic clinical registry for our inflammatory bowel disease team. It has enabled significant advances in disease modeling with over 20 major publications in the last 3 years.
He also serves as the site Principal Investigator of an industry-sponsored FDA registration trial of obeticholic acid therapy for primary sclerosing cholangitis.